A science ministry committee of experts on Wednesday approved Japan’s first research involving the injection of human induced pluripotent stem (iPS) cells into fertilized animal eggs with the aim of growing human organs.
Life Science & Medical Technology
Mitsuhiro Ebara believes plastic sheets called “smart polymers” may one day prove to be a cheap solution to curing cancer.
Fujifilm Corp. has said it will team up with Germany’s Bayer AG on the development of a new immune-based cancer therapy platform using induced pluripotent stem, or iPS, cells that come from someone other than the patient.
SoftBank Group's Vision Fund is venturing further into the wellness industry with its second investment in as many weeks after leading a funding round for San Francisco-based Collective Health.
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care.
Japan materials group Toray Industries will apply this year for fast-track government approval to sell a cancer screening test that requires only one drop of blood.
Ahead of World No Tobacco Day on Friday, smokers who have been fighting a lonely battle against nicotine addiction were given another option in their quest to kick the habit.
Japan's national medical insurance system was given the go-ahead on Wednesday to cover leukemia treatment using expensive Kymriah from Swiss drugmaker Novartis.
Takeda Pharmaceutical CEO Christophe Weber promised greater cost savings from the company's purchase of Irish drugmaker Shire, lifting the savings target by 43% versus its earlier forecast.
Takeda Pharmaceutical on Thursday said it will sell its dry-eye drug business to Swiss rival Novartis for up to $5.3 billion.